Microcarriers Market

The global microcarriers market in terms of revenue was estimated to be worth $2.0 billion in 2023 and is poised to reach $3.3 billion by 2028, growing at a CAGR of 10.0% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of the microcarriers industry is largely driven by the increasing R&D spending for biopharmaceutical production, growing demand for mAbs and biosimilars, and growing preference for single-use technologies.

Microcarriers Market- Global Forecast to 2028

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Microcarriers Market

Microcarriers Market Dynamics

DRIVER: Growing adoption of microcarriers for cell-based vaccine production

The increasing demand for cell-based vaccines to combat a wide range of infectious diseases, including, influenza, HIV, and emerging pathogens, is fueling the growth of the microcarrier market. Cell-based vaccine production relies on microcarriers to support high-density cell culture, allowing for rapid &and scalable vaccine manufacturing. These microcarriers facilitate improved vaccine yields, ensuring a more efficient response to global health threats and pandemic preparedness. The flexibility and versatility of cell-based platforms make microcarriers a critical component in addressing the growing demand for effective &and timely vaccine solutions.

RESTRAINT: High cost of cell biology research

Cell biology involves extensive R&D on innovative therapies such as stem cell and gene therapies. The equipment, reagents, and other products associated with research of the highest quality to provide accurate results. Owing to the growing need to maintain high-quality standards with high-grade products and comply with guidelines set up by regulatory bodies, the cost of cell biology research has risen considerably. Researchers and small-scale pharmaceutical and biotechnology companies may face budget constraints and prioritization of funds, which can limit its capacity to invest in microcarrier-based systems. Consequently, the growth of the microcarrier market is impeded, as potential customers and adopters are deterred by the financial barriers associated with cell biology research.

OPPORTUNITY: Rising demand for 3D Cell culture

The surge in demand for 3D cell culture systems and investments in this technology directly propel the need for microcarriers. Microcarriers serve as foundational elements, enabling cells to attach and grow in a three-dimensional setup, crucial for creating complex tissue-like structures. Their role in scalable production, facilitating precise culture conditions, and supporting 3D bioreactor systems aligns with the requirements of 3D cell culture methodologies, driving their increased adoption in biomedical research and therapeutic development.

CHALLENGE: High costs associated with serum-free media

The unavailability of inexpensive serum-free media is expected to pose a challenge to market growth. Serum-free media is preferred over serum-containing media due to its defined composition, lot-to-lot consistency, and reduced risk of introducing adventitious agents. However, serum-free media is more expensive than serum-containing media, and the screening process of serum can be very costly and time-consuming. The lengthy adaptation process before serum-free media can be incorporated into a production process, along with the unreliability of early serum-free media, has often been a barrier to change. The use of serum-free media formulations is cell line-specific and requires optimization for microcarrier culture.

This cost barrier limits the scalability and adoption of microcarrier-based cell culture systems, which are crucial for various applications like regenerative medicine, vaccine development, and cell therapy.

Global In Microcarriers Market Ecosystem Analysis

The ecosystem of microcarrier consists of end users from pharmaceutical & biotechnology companies, contract research organizations & contract manufacturing organizations, academic and research institutes, and cell banks, microcarrier cell culture products providers, instrument & reagent suppliers, technology providers, regulatory authorities (ensuring compliance and safety), and collaborative networks promoting knowledge sharing and collaboration. These stakeholders interact and collaborate to drive the advancement of microcarrier cell culture products, enhance bioprocessing activities, and support development of new therapeutics.

Consumables held a dominant share in the product segment in the microcarriers industry

Based on the product, the microcarriers industry has been segmented into consumables and equipment. In 2022, consumables hold the largest share of the microcarriers market due to repetitive purchase of consumables and increasing adoption of high-quality media and reagents for cell culture.

The biopharmaceutical production segment of the microcarriers industry is expected to register the fastest growth during the forecast period.

Based on the applications of microcarriers, the microcarriers market has been segmented into biopharmaceutical production, tissue engineering and regenerative medicine, and other applications. In 2022, biopharmaceutical production accounted for the largest share. The significant dominance of the biopharmaceutical production sector is due to the substantial growth in commercial activities among major pharmaceutical firms, rising regulatory authorizations for vaccines developed through cell culture, and the escalating need for monoclonal antibodies (mAbs). Notably, the Antibody Society Organization reported approximately 38 antibody therapeutics approved in the US and Europe from 2020 to 2022.

To know about the assumptions considered for the study, download the pdf brochure

North America accounted for the largest share in microcarriers industry in 2022

Geographically, the Microcarriers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the dominant share followed by Europe.

In North America the widespread adoption of microcarrier cell culture thrives due to the region's robust biopharmaceutical industry, supported by its capacity to produce intricate biologics. Additionally, the presence of leading research institutions and innovation hubs fosters a culture of technological advancement, promoting the integration of cutting-edge techniques like microcarrier systems. Favorable regulatory landscapes and well-developed infrastructure further bolster the implementation of these advanced cell culture methods, ensuring adherence to stringent quality standards. Moreover, the growing focus on personalized medicine in the US drives the use of microcarrier cell culture for tailored cell therapies, catering to the escalating demand for individualized treatments in the field of regenerative medicine.

Key players in the global Microcarriers market include Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), Danaher Corporation, (US), Merck KGaA (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland), Getinge AB (Sweden), ChemoMetec (Denmark), Esco Lifesciences Group Ltd (Singapore), Entegris (US), bbi-biotech GmbH (Germany), STEMCELL Technologies (Canada), Stobbe Group (Denmark), Distek, Inc. (US), Bionet (Spain), &G Technologies, Inc. (US), Tantti (Taiwan), Kühner AG (Switzerland), PBS Biotech, Inc. (US), REPROCELL Inc. (Japan), Meissner Filtration Products, Inc. (US), and Smart MCs PTY LTD (Australia).

Scope of the Microcarriers Industry

This report categorizes the microcarriers market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Consumables
• Media
  • Serum-based Media
  • Serum-free Media
  • Other Media
• Reagents
• Microcarrier Beads
  • Cationic Beads
  • Collagen-coated Beads
  • Protein-coated Beads
  • Untreated Beads
  • Other Microcarrier Beads
• Other Consumables
• Equipment
• Bioreactors
  • Single-use Bioreactors
  • Stainless-steel Bioreactors
• Culture Vessels
• Filtration and Separation Equipment
• Cell Counters
• Other Equipment

By Application

• Biopharmaceutical Production
• Vaccine Production
• Therapeutic Proteins
• Tissue Engineering and Regenerative Medicine

By Therapy

• Cell & Gene Therapy
• Other Tissue Engineering and Regenerative Medicine Applications

By Cell Type

• Stem Cells
  • Hematopoietic Stem Cells (HSCs
  • Mesenchymal Stem Cells (MSCs)
  • Induced Pluripotent Stem CELLS (iPSCs)
  • Other Stem Cells
• Immune Cells
  • T-Cells
  • NK Cells
  • Other Immune Cells
• Other Cell Types

By End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations and Contract Manufacturing Organizations (CROs and CMOs)
• Academic & Research Institutes
• Cell Banks

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • China
  • India
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • RoLATAM
• Middle East & Africa
  • Middle East
  • Africa

Recent Developments of Microcarriers Industry

• In September 2023, Thermo Fisher Scientific (US) launched Gibco CTS Detachable Dynabeads, a groundbreaking platform with an innovative active release mechanism designed for clinical and commercial cell therapy manufacturing.
• In January 2021, Sartorius AG (Germany) collaborated with RoosterBio Inc. (US), to advance cell and gene therapy manufacturing, aiming to scale up human mesenchymal stem/stromal cell (hMSC) manufacturing for regenerative medicine and accelerate the development and commercialization of cell-based regenerative cures. This collaboration will leverage the best-in-class solutions of both companies to significantly reduce process development efforts, industrialize the supply chain, and simplify multiple steps in therapeutic development.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst